Omnicell Inc (OMCL)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $1.61B
Last updated: Nov 17, 2026 at 11:06 AM ET
Omnicell Inc (OMCL) Earnings: Report Dates and Results
Omnicell (OMCL) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Omnicell reported EPS of $0.36, above the $0.24 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OMCL has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.5% below the $0.40 reported for the quarter ended Dec 31, 2025.
OMCL Earnings Call
The latest OMCL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, OMCL beat 34, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $307.85M, down 0.9% from $310.63M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.36 | $0.24 | N/A | +50.00% | Beat | -29.4% | 8 | 1 up, 5 down | Oct 29, 2026 | $307.85M |
| Jun 30, 2026 | $0.70 | $0.31 | N/A | +125.81% | Beat | +55.6% | 8 | 7 up, 0 down | Jul 30, 2026 | $312.21M |
| Mar 31, 2026 | $0.55 | $0.33 | $0.29 - $0.41 | +66.67% | Beat | +111.5% | 8 | 1 up, 0 down | Apr 28, 2026 | $309.88M |
| Dec 31, 2025 | $0.40 | $0.50 | $0.46 - $0.61 | -20.00% | Miss | -33.3% | 8 | 1 up, 0 down | Feb 5, 2026 | $313.98M |
| Sep 30, 2025 | $0.51 | $0.36 | $0.32 - $0.42 | +41.67% | Beat | -8.9% | 8 | 3 up, 3 down | Oct 30, 2025 | $310.63M |
| Jun 30, 2025 | $0.45 | $0.27 | $0.22 - $0.32 | +66.67% | Beat | -11.8% | 7 | 1 up, 0 down | Jul 31, 2025 | $290.56M |
| Mar 31, 2025 | $0.26 | $0.20 | $0.16 - $0.25 | +30.00% | Beat | +766.7% | 8 | 0 up, 0 down | May 6, 2025 | $269.67M |
| Dec 31, 2024 | $0.60 | $0.58 | $0.55 - $0.61 | +3.45% | Beat | +81.8% | 9 | 9 up, 0 down | Feb 6, 2025 | $306.88M |
| Sep 30, 2024 | $0.56 | $0.42 | $0.34 - $0.47 | +33.33% | Beat | -9.7% | 8 | 0 up, 0 down | Oct 30, 2024 | $282.42M |
| Jun 30, 2024 | $0.51 | $0.14 | $0.10 - $0.18 | +264.29% | Beat | -10.5% | 9 | 1 up, 0 down | Aug 1, 2024 | $276.79M |
| Mar 31, 2024 | $0.03 | -$0.09 | -$0.21 - -$0.04 | +133.33% | Beat | -92.3% | 9 | 0 up, 0 down | May 2, 2024 | $246.15M |
| Dec 31, 2023 | $0.33 | $0.15 | $0.09 - $0.22 | +120.00% | Beat | 0.0% | 9 | 0 up, 0 down | Feb 8, 2024 | $258.85M |
| Sep 30, 2023 | $0.62 | $0.48 | $0.42 - $0.49 | +29.17% | Beat | -38.0% | 7 | 1 up, 0 down | Nov 2, 2023 | $298.66M |
| Jun 30, 2023 | $0.57 | $0.28 | $0.24 - $0.34 | +103.57% | Beat | -32.1% | 9 | 0 up, 0 down | Aug 1, 2023 | $298.97M |
| Mar 31, 2023 | $0.39 | $0.07 | $0.02 - $0.11 | +457.14% | Beat | -53.0% | 9 | 0 up, 0 down | May 2, 2023 | $290.63M |
| Dec 31, 2022 | $0.33 | $0.09 | $0.03 - $0.21 | +266.67% | Beat | -64.1% | 8 | 0 up, 1 down | Feb 28, 2023 | $297.67M |
| Sep 30, 2022 | $1.00 | $0.95 | $0.83 - $0.99 | +5.26% | Beat | -7.4% | 9 | 0 up, 0 down | Nov 2, 2022 | $348.06M |
| Jun 30, 2022 | $0.84 | $0.85 | N/A | -1.18% | Miss | -13.4% | N/A | 0 up, 0 down | Aug 4, 2022 | $331.39M |
| Mar 31, 2022 | $0.83 | $0.68 | $0.66 - $0.72 | +22.06% | Beat | 0.0% | 6 | 0 up, 0 down | Apr 28, 2022 | $318.83M |
| Dec 31, 2021 | $0.92 | $0.92 | $0.87 - $0.95 | 0.00% | In line | +1.1% | 7 | 0 up, 0 down | Feb 14, 2022 | $311.03M |
| Sep 30, 2021 | $1.08 | $0.91 | $0.88 - $0.94 | +18.68% | Beat | +80.0% | 8 | N/A | Nov 2, 2021 | $296.40M |
| Jun 30, 2021 | $0.97 | $0.83 | $0.77 - $0.87 | +16.87% | Beat | +162.2% | 9 | N/A | Jul 29, 2021 | $272.74M |
| Mar 31, 2021 | $0.83 | $0.66 | $0.64 - $0.67 | +25.76% | Beat | +25.8% | 5 | N/A | Apr 29, 2021 | $251.84M |
| Dec 31, 2020 | $0.91 | $0.82 | $0.72 - $0.87 | +10.98% | Beat | +18.2% | 6 | N/A | Feb 1, 2021 | $249.20M |
| Sep 30, 2020 | $0.60 | $0.49 | $0.44 - $0.50 | +22.45% | Beat | -21.1% | 7 | N/A | Oct 27, 2020 | $213.70M |
| Jun 30, 2020 | $0.37 | $0.23 | $0.01 - $0.46 | +60.87% | Beat | -44.8% | 8 | N/A | Jul 28, 2020 | $199.62M |
| Mar 31, 2020 | $0.66 | $0.51 | $0.36 - $0.63 | +29.41% | Beat | +8.2% | 6 | N/A | May 7, 2020 | $229.69M |
| Dec 31, 2019 | $0.77 | $0.78 | $0.77 - $0.79 | -1.28% | Miss | +10.0% | 7 | N/A | Feb 6, 2020 | $248.29M |
| Sep 30, 2019 | $0.76 | $0.71 | $0.70 - $0.72 | +7.04% | Beat | +20.6% | 7 | N/A | Oct 24, 2019 | $228.81M |
| Jun 30, 2019 | $0.67 | $0.63 | $0.62 - $0.64 | +6.35% | Beat | +45.7% | 7 | N/A | Jul 25, 2019 | $217.41M |
| Mar 31, 2019 | $0.61 | $0.41 | $0.39 - $0.41 | +48.78% | Beat | +110.3% | 7 | N/A | Apr 25, 2019 | $202.52M |
| Dec 31, 2018 | $0.70 | $0.67 | $0.65 - $0.68 | +4.48% | Beat | +29.6% | 7 | N/A | Feb 7, 2019 | $211.75M |
| Sep 30, 2018 | $0.63 | $0.56 | $0.54 - $0.57 | +12.50% | Beat | +50.0% | 7 | N/A | Oct 25, 2018 | $204.27M |
| Jun 30, 2018 | $0.46 | $0.39 | $0.38 - $0.41 | +17.95% | Beat | +48.4% | 7 | N/A | Jul 26, 2018 | $188.67M |
| Mar 31, 2018 | $0.29 | $0.25 | $0.24 - $0.27 | +16.00% | Beat | +383.3% | 7 | N/A | Apr 26, 2018 | $182.62M |
| Dec 31, 2017 | $0.54 | $0.52 | $0.51 - $0.53 | +3.85% | Beat | +45.9% | 7 | N/A | Feb 1, 2018 | $196.37M |
| Sep 30, 2017 | $0.42 | $0.42 | N/A | 0.00% | In line | +5.0% | N/A | N/A | Oct 26, 2017 | $186.75M |
| Jun 30, 2017 | $0.31 | $0.23 | N/A | +34.78% | Beat | -18.4% | N/A | N/A | Jul 27, 2017 | $181.04M |
| Mar 31, 2017 | $0.06 | $0.02 | N/A | +200.00% | Beat | -82.9% | N/A | N/A | May 4, 2017 | $148.55M |
| Dec 31, 2016 | $0.37 | $0.41 | N/A | -9.76% | Miss | -7.5% | N/A | N/A | Feb 15, 2017 | $175.26M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.62, down 4.7% from the year before. It was $1.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.62 | -4.7% |
| Dec 31, 2024 | $1.70 | -11.0% |
| Dec 31, 2023 | $1.91 | -36.3% |
| Dec 31, 2022 | $3.00 | -21.1% |
| Dec 31, 2021 | $3.80 | +49.6% |
| Dec 31, 2020 | $2.54 | -9.6% |
| Dec 31, 2019 | $2.81 | +35.1% |
| Dec 31, 2018 | $2.08 | +56.4% |
| Dec 31, 2017 | $1.33 | -11.3% |
| Dec 31, 2016 | $1.50 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,900 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,863 | 13 | |
| 2026Q2 | Jun 30, 2026 | 7,161 | 12 | |
| 2026Q1 | Mar 31, 2026 | 5,321 | 12 | |
| 2025Q4 | Dec 31, 2025 | 8,271 | 14 | |
| 2025Q3 | Sep 30, 2025 | 5,813 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,831 | 12 | |
| 2025Q1 | Mar 31, 2025 | 6,181 | 12 | |
| 2024Q4 | Dec 31, 2024 | 5,974 | 11 |
2026Q3 Earnings Call
Opening remarks
David Unger VP of Investor Relations Good morning, and welcome to the Omnicell Third Quarter 2026 financial results conference call. My name is David Unger, Vice President of Investor Relations. On the call with me today are Randall Lipps, Chairman, Chief Executive Officer, and Founder; Nnamdi Njoku, President and Chief Operating Officer; and Baird Radford, Executive Vice President and Chief Financial Officer. Before we begin, I would like to remind you that today's call will include forward-looking statements within the meaning of federal securities laws, including statements regarding our financial outlook, business expectations, and strategic priorities. These forward-looking statements are based on current expectations and assumptions as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For additional information concerning these risks and uncertainties, please refer to our earnings press release issued this morning, our annual report on Form 10-K filed with the SEC on February 26, 2026, and our subsequent SEC filings. We disclaim any obligation to update any forward-looking statements except as required by law. During this call, we will also discuss certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP measures are included in our third quarter 2026 earnings press release, available on the investor relations section of our website at ir.omnicell.com. Turning to today's agenda. Randall will begin with an overview of our third quarter performance and strategic priorities. Nnamdi will then provide an update on our operational execution and key initiatives, followed by Baird, who will review our financial results and updated outlook. We will then open the call for questions. With that, I will turn the call over to Randall. Randall?
Randall Lipps Chairman, CEO, and Founder Good morning, everyone, and thank you for joining us. In the third quarter 2026, we delivered another quarter of strong execution. Total revenue was $308 million, and non-GAAP EBITDA was $45 million, both above the high end of our previously shared guidance. These results reflect the execution-oriented approach we've taken throughout the year and reinforce our confidence in the strategy we're pursuing in autonomous medication management. Medication management remains foundational to how health systems operate. We have seen that it is difficult for a hospital to achieve its clinical and operational objectives without getting medication management right, and that reality continues to underpin the long-term demand we see. Before sharing additional perspectives on our business, I want to touch on our sixth annual Illuminate event, held on September 29, where we brought customers and prospects together to discuss our strategy for medication management.
Frequently Asked Questions About OMCL
When is Omnicell's next earnings date?
Omnicell's next earnings report is expected for Feb 3, 2027.
Did OMCL beat earnings estimates last quarter?
Yes. Omnicell reported EPS of $0.36 for the quarter ended Sep 30, 2026, above the $0.24 estimate, a 50.00% surprise.
What EPS do analysts expect from OMCL next quarter?
The consensus EPS estimate for Omnicell for the quarter ending Dec 31, 2026 is $0.39 from 10 analysts, with estimates from $0.14 to $0.45.
How often does OMCL beat earnings estimates?
Omnicell beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +45.53%.
OMCL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts